Download Rabbit anti-WNT3 Rabbit anti-WNT3

Qty: 100µg/400 µL
Rabbit anti-WNT3
Catalog No. 38-2700
Lot No.
Rabbit anti-WNT3
FORM
This polyclonal antibody is supplied as a 400 µL aliquot at a concentration of 0.25 mg/mL in phosphate buffered saline
(pH 7.4) containing 0.1% sodium azide. This antibody is epitope-affinity purified from rabbit antiserum.
PAD: ZMD.357
IMMUNOGEN
Synthetic peptide derived from an internal region of the human WNT3 protein.
SPECIFICITY
This antibody reacts with mouse WNT3 protein. On Western blots, it identifies a band at ~40 kDa. Two additional nonspecific bands at ~50 kDa and ~60 kDa are observed in both WNT3-transfected and vector-only cell lysates.
REACTIVITY
Reactivity has been confirmed with WNT-pCMV-tag2-transfected 293T cell lysates. Based upon amino acid sequence
homology, reactivity with human, rat and chicken WNT3 is also expected.
Sample
Mouse
Human
Rat
Chicken
Western
Blotting
+++*
ND
ND
ND
Immunoprecipitation
(native)
+++*
ND
ND
ND
(Excellent +++, Good++, Poor +, No reactivity 0, Not applicable N/A, Not Determined ND)
*This antibody recognizes overexpressed protein. Reactivity with endogenous protein has not been verified.
USAGE
Working concentrations for specific applications should be determined by the investigator. Appropriate concentrations will be
affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method,
temperature and length of incubations, etc. The suitability of this antibody for applications other than those listed below has
not been determined. The following concentration ranges are recommended starting points for this product.
Western Blotting: 1-3 µg/mL
Immunoprecipitation (native): 7 µg/reaction
STORAGE
Store at 2-8°C for up to one month. Store at –20°C for long-term storage. Avoid repeated freezing and thawing.
(cont’d)
www.invitrogen.com
Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [email protected]
PI382700
(Rev 10/08) DCC-08-1089
Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website,
www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these
products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
(38-2700 cont’d)
BACKGROUND
WNTs have diverse roles in governing cell fate, proliferation, migration, and polarity during development, particularly in
embryogenesis and carcinogenesis1-3. WNTs are transduced through at least three distinct intracellular signaling pathways,
including the canonical WNT/β-catenin, WNT/Ca2+ and WNT polarity (also called the ‘planar polarity’ pathway)2, 4,5 pathways.
Distinct sets of WNT and Frizzled ligand-receptor pairs activate each of these pathways and lead to unique cellular
responses. The WNT/β-catenin pathway primarily regulates cell fate determination during development, whereas the main
function of the WNT polarity pathway is the regulation of cytoskeletal organization.
WNT3 is expressed in embryonic mouse brain (with peak expression at around day 12 of gestation) and at low levels in the
6
adult. It is present in the cerebellum during mouse development, and is restricted to the Purkinje cell layer in the adult
7,8
mouse. WNT3 is required for normal limb development and plays an important role in the establishment of the apical
9
ectodermal ridge (AER). In motorneurons, WNT3 is a retrograde signal that controls terminal branching of muscle
10
afferents. WNT3 is highly expressed in human cancer cell lines including A549 (lung cancer), MKN45 (gastric cancer) and
11,12
Upregulation of WNT3 has also been observed in primary breast cancer and rectal cancer
MCF-7 (breast cancer).
specimins.11
REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
Cadigan KM and Nusse R. Genes Dev 11:3286-3305, 1997.
Miller JR, et al. Oncogene 18:7860-7872, 1999.
Polakis P. Genes Dev 14:1837-1851, 2000.
Adler, PN and Lee H. Curr Opin Cell Biol 13:635-640, 2001.
Kuhl M, et al. Trends Genet 16:279-283, 2000.
Roelink H, et al. PNAS 87:819-827, 1990.
Salinas PC, et al. Development 120:1277-1286, 1994.
Greco TL, et al. Genes Dev 10:313-324, 1996.
Barrow JR, et al. Genes Dev 17:394-409, 2003.
Krylova O, et al. Neuron 35:1043-1056, 2002.
Katoh M. Int J Oncol 19:977-982, 2001.
Katoh M. Int J Oncol 20:373-377, 2002.
RELATED PRODUCTS
Product
Protein A
rec-Protein G
Conjugate
Purified
FITC
TRITC
Cy™3
Cy™5
HRP
AP
Biotin
®
Conjugate
®
Sepharose 4B
®
Sepharose 4B
ZyMAX™ Goat x Rabbit IgG
(H+L)
81-6100
81-6111
81-6114
81-6115
81-6116
81-6120
81-6122
81-6140
Cat. No.
10-1041
10-1241
ZyMAX™ Goat x Mouse IgG
(H+L)
81-6500
81-6511
81-6514
81-6515
81-6516
81-6520
81-6522
81-6540
®
Zymed and ZyMAX™ are trademarks of Zymed Laboratories Inc. Cy™ and Sepharose are trademarks of Amersham Biosciences Ltd.
For Research Use Only
www.invitrogen.com
Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [email protected]
PI382700
(Rev 10/08) DCC-08-1089
Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website,
www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these
products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.